12:00 AM
 | 
May 17, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enbrel etanercept: Phase III data; marketed to treat moderately to severely active RA in patients who have an inadequate response to one or more disease modifyi

Data from 633 patients with early, active RA in a Phase III trial comparing Enbrel to methotrexate showed that Enbrel met its primary end points of a reduction in the signs and symptoms...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >